Journal of Neural Transmission

, Volume 113, Issue 11, pp 1771–1778 | Cite as

CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies

  • M. Bibl
  • B. Mollenhauer
  • H. Esselmann
  • P. Lewczuk
  • C. Trenkwalder
  • P. Brechlin
  • E. Rüther
  • J. Kornhuber
  • M. Otto
  • J. Wiltfang
Article

Summary.

Differential diagnosis of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) is often crucial. CSF Tau protein and Amyloid-beta (Aβ) peptides have shown diagnostic value for the diagnosis of AD, but discrimination from DLB was poor.

Herein, we investigate CSF of 18 patients with probable AD, 25 with probable DLB and 14 non-demented disease controls (NDC) by Aβ-SDS-PAGE/immunoblot and commercially available ELISAs for Aβ1-42 and tau. CSF Aβ peptide patterns and tau exhibited disease specific alterations among AD and DLB. The ratio of Aβ1-42 to Aβ1-38 and Aβ1-42 to Aβ1-37, respectively, in combination with absolute tau, yielded a sensitivity and specificity of 100 and 92%, respectively. We conclude that CSF Aβ peptide patterns and tau levels reflect disease-specific pathophysiological pathways of these dementias as distinct neurochemical phenotypes. Combined evaluation of these biomarkers provides a reasonable accuracy for differential diagnosis of AD and DLB.

Keywords: Alzheimer’s dementia, Lewy-body dementia, cerebrospinal fluid, amyloid-β peptides, tau protein, biomarker 

Abbreviations:

Aβ peptides

amyloid-beta peptides

Aβ-SDS-PAGE/immunoblot

amyloid-beta-sodium-dodecyl-sulphate-polyacrylamide-gel-electrophoresis with western immunoblot

AD

Alzheimer’s disease

ApoE ɛ4

apolipoprotein E allele ɛ4

APP

beta-amyloid precursor protein

bicine

N,N′-bis-[2-hydroxyethyl]glycine

CCD-camera

charge coupled device camera

CSF

cerebrospinal fluid

Ct-elongated

carboxyterminally elongated

Ct-truncated

carboxyterminally truncated

DLB

dementia with Lewy bodies

ECL

enhanced chemiluminescence

ELISA

Enzyme Linked Immunosorbent Assay

MMSE

Mini-Mental-Status Examination

NINCDS-ADRDA

National Institute Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association

ND

non-demented

PDD

Parkinson’s disease dementia

PVDF

polyvinylidene difluoride

SDS

sodium dodecyl sulphate

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreasen, N, Sjogren, M, Blennow, K 2003CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42World J Biol Psychiatry4147155PubMedCrossRefGoogle Scholar
  2. Andreasen, N, Minthon, L, Davidsson, P, Vanmechelen, E, Vanderstichele, H, Winblad, B, Blennow, K 2001Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practiceArch Neurol58373379PubMedCrossRefGoogle Scholar
  3. Bibl, M, Esselmann, H, Otto, M, Lewczuk, P, Cepek, L, Rüther, E, Kornhuber, J, Wiltfang, J 2004Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aβ peptidesElectrophoresis2529122918PubMedCrossRefGoogle Scholar
  4. Blacker, D, Albert, MS, Bassett, SS, Go, RC, Harrell, LE, Folstein, MF 1994Reliability and validity of NINCDS-ARDA criteria for Alzheimer’s disease. The National Institute of Mental Health Genetics InitiativeArch Neurol5111981204PubMedGoogle Scholar
  5. Citron, M, Diehl, TS, Gordon, G, Biere, AL, Seubert, P, Selkoe, DJ 1996Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activitiesProc Natl Acad Sci USA931317013175PubMedCrossRefGoogle Scholar
  6. Folstein, MF, Folstein, SE, McHugh, PR 1975“Mini-mental state”: a practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res12189198PubMedCrossRefGoogle Scholar
  7. Glenner, GG, Wong, CW 1984Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochem Biophys Res Commun120885890PubMedCrossRefGoogle Scholar
  8. Haas, C, Selkoe, DJ 1993Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptideCell7510391042CrossRefGoogle Scholar
  9. Hansen, LA, Masliah, E, Galasko, D, Terry, RD 1993Palque only Alzheimer disease is usually the Lewy body variant, and vice versaJ Neuropathol Exp Neurol52648654PubMedGoogle Scholar
  10. Hulstaert, F, Blennow, K, Ivanoiu, A, Schoonderwald, HC, Riemenschneider, M, De Deyn, PP, Bancher, C, Cras, P, Wiltfang, J, Mehta, PD, Iqbal, K, Pottel, H, Vanmechelen, E, Vanderstichele, H 1999Improved discrimination of AD-patients using β-amyloid (1-42) and tau levels in CSFNeurology5215551562PubMedGoogle Scholar
  11. Janek, K, Rothemund, S, Gast, K, Beyermann, M, Zipper, J, Fabian, H, Bienert, M, Krause, E 2001Study of the conformational transition of Abeta (1-42) using D-amino acid replacement analoguesBiochemistry4054575463PubMedCrossRefGoogle Scholar
  12. Jendroska K, Kashiwagi M, Sassoon J, Daniel SE (1997) Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm [Suppl 51]: 137–144Google Scholar
  13. Kanemaru, K, Kameda, N, Yamanouchi, H 2000Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodiesNeurology5418751876PubMedGoogle Scholar
  14. Lee, VMY, Balin, BJ, Otvos, L, Trojanowski, JQ 1991A68: a major subunit of paired helical filaments and derivatized forms of normal tauScience251675678PubMedCrossRefGoogle Scholar
  15. Lewczuk, P, Esselmann, H, Otto, M, Maler, JM, Henkel, AW, Henkel, MK, Eikenberg, O, Antz, C, Krause, WR, Reulbach, U, Kornhuber, J, Wiltfang, J 2004Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta 42, Abeta42/Abeta40 ratio and total tauNeurobiol Aging25273281PubMedCrossRefGoogle Scholar
  16. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM 1984Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s diseaseNeurology34939944PubMedGoogle Scholar
  17. McKeith, IG, Galasko, D, Kosaka, K, Perry, EK, Dickson, DW, Hansen, LA, Salmon, DP, Lowe, J, Mirra, SS, Byrne, EJ, Lennox, G, Quinn, NP, Edwardson, JA, Ince, PG, Bergeron, C, Bruns, A, Miller, BL, Lovestone, S, Collerton, D, Jansen, EN, Ballard, C, de Vos, RA, Wilcock, GK, Jellinger, KA, Perry, RH 1996Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopNeurology4711131124PubMedGoogle Scholar
  18. Merdes, AR, Hansen, MD, Jeste, DV, Galasko, D, Hofstetter, CR, Ho, GJ, Thal, LJ, Corey-Bloom, J 2003Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy-BodiesNeurology6015861590PubMedGoogle Scholar
  19. Molina, L, Touchon, J, Herpe, M, Lefranc, D, Duplan, L, Cristol, JP, Sabatier, R, Vermersch, P, Pau, B, Mourton-Gilles, C 1999Tau and Apo E in CSF: potential aid for discriminating Alzheimer’s disease from other dementiasNeuroreport1034913495PubMedGoogle Scholar
  20. Mollenhauer, B, Cepek, L, Bibl, M, Wiltfang, J, Schulz-Schaeffer, W, Ciesielczyk, B, Reiber, H, Neumann, M, Steinacker, P, Poser, S, Trenkwalder, C, Otto, M 2005Tau protein, beta-amyloid (1-42) and S100B protein in cerebrospinal fluid of patients with Dementia with Lewy BodiesDement Cogn Geriatr Disord19164170CrossRefGoogle Scholar
  21. Motter, R, Vigo-Pelfrey, C, Kholodenko, D, Barbour, R, Johnson-Wood, K, Galasko, D, Chang, L, Miller, B, Clark, C, Green, R 1995Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s diseaseAnn Neurol38643648PubMedCrossRefGoogle Scholar
  22. Otto, M, Wiltfang, J, Cepek, L, Neumann, M, Mollenhauer, B, Steinacker, P, Ciesielczyk, B, Schulz-Schaeffer, W, Kretzschmar, HA, Poser, S 2002Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob diseaseNeurology58192197PubMedGoogle Scholar
  23. Pitschke, M, Prior, R, Haupt, M, Riesner, D 1998Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopyNat Med4832834PubMedCrossRefGoogle Scholar
  24. Podlisny, MB, Ostaszewski, BL, Squazzo, SL, Koo, EH, Rydell, RE, Teplow, DB, Selkoe, DJ 1995Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell cultureJ Biol Chem27095649570PubMedCrossRefGoogle Scholar
  25. Tschampa, HJ, Schulz-Schaeffer, W, Wiltfang, J, Poser, S, Otto, M, Neumann, M, Kretzschmar, HA 2001Decreased CSF amyloid 42 and normal tau levels in dementia with Lewy bodiesNeurology56576PubMedGoogle Scholar
  26. Verbeek, MM, de Jong, D, Kremer, HPH 2003Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseasesAnn Clin Biochem402540PubMedCrossRefGoogle Scholar
  27. Wiltfang, J, Esselmann, H, Bibl, M, Smirnov, A, Otto, M, Paul, S, Schmid, B, Klafki, H-W, Maler, M, Dyrks, T, Bienert, M, Beyermann, M, Rüther, E, Kornhuber, J 2002Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and patients with chronic neuroinflammationJ Neurochem81481496PubMedCrossRefGoogle Scholar
  28. Wiltfang, J, Esselmann, H, Cupers, P, Neumann, M, Kretzschmar, H, Beyermann, M, Schleuder, D, Jahn, H, Rüther, E, Kornhuber, J, Annaert, W, De Strooper, B, Saftig, P 2001Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cellsJ Biol Chem2764264542657PubMedCrossRefGoogle Scholar
  29. Wiltfang, J, Esselmann, H, Smirnov, A, Bibl, M, Cepek, L, Steinacker, P, Mollenhauer, B, Buerger, K, Hampel, H, Paul, S, Neumann, M, Maler, M, Kornhuber, J, Kretzschmar, HA, Poser, S, Otto, M 2003Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseaseAnn Neurol54263267PubMedCrossRefGoogle Scholar
  30. Wiltfang, J, Lewczuk, P, Riederer, P, Grunblatt, E, Hock, C, Scheltens, P, Hampel, H, Vanderstichele, H, Iqbal, K, Galasko, D, Lannfelt, L, Otto, M, Esselmann, H, Henkel, AW, Kornhuber, J, Blennow, K 2005Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementiaWorld J Biol Psychiatry66984PubMedGoogle Scholar
  31. World Medical Organisation1996Declaration of HelsinkiBritish Medical Journal31314481449Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. Bibl
    • 1
  • B. Mollenhauer
    • 2
  • H. Esselmann
    • 3
  • P. Lewczuk
    • 3
  • C. Trenkwalder
    • 4
  • P. Brechlin
    • 1
  • E. Rüther
    • 1
  • J. Kornhuber
    • 3
  • M. Otto
    • 5
  • J. Wiltfang
    • 3
  1. 1.Department of PsychiatryUniversity of GoettingenGoettingenGermany
  2. 2.Brigham and Women’s Hospital, Center for Neurologic DiseasesHarvard Medical SchoolBostonUSA
  3. 3.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany
  4. 4.University of GoettingenParacelsus-Elena KlinikGermany
  5. 5.Department of NeurologyUniversity of UlmGermany

Personalised recommendations